Genmab — Juli 2019
-
God morgen.

-
Har ikke lige fuldt debatten i går, men Andrew har skrevet, at man har trukket IND`en og istedet indsendt en CTA for CD40/4-1BB. Desuden at man prioriterer PD-L1/4-1BB højere, så det lyder under alle omstændigheder ikke alt for lovende med GEN1042
-
Har GEN1042 også et andet navn? Jeg kan intet finde om GEN1042 på Genmab's hjemmeside.
-
-
Andrew Carlsen We are fortunate enough to have two exciting programs with our partner BioNTech
and the reason for PD-L1/41BB being slightly further progressed has to do with
prioritization and resource allocation. With regards to the 4-1BB arm we have not
disclosed this to the public -
Teva aktien på laveste niveau siden 90 erne. Nu mindre værd end Genmab. ;-). https://medwatch.dk/Medicinal___Biotek/article11503235.ece
-
er dette en gammel nyhed - har ikke set det før
-
Milliardaftale sender Genmab i kapløb mod farmakæmpe og gammel rival
Genmab har indgået en mulig milliardalliance om udvikling af ny type immunterapi mod kræft, som blandt andre den tyske medicinalkoncern Boehringer Ingelheim og en af det danske biotekselskabs tidligere ærkerivaler også satser på.
(medwatch.dk)
-
pensionist - tak for info
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind